SG11202001063QA - Clec9a binding agents and use thereof - Google Patents

Clec9a binding agents and use thereof

Info

Publication number
SG11202001063QA
SG11202001063QA SG11202001063QA SG11202001063QA SG11202001063QA SG 11202001063Q A SG11202001063Q A SG 11202001063QA SG 11202001063Q A SG11202001063Q A SG 11202001063QA SG 11202001063Q A SG11202001063Q A SG 11202001063QA SG 11202001063Q A SG11202001063Q A SG 11202001063QA
Authority
SG
Singapore
Prior art keywords
binding agents
clec9a binding
clec9a
agents
binding
Prior art date
Application number
SG11202001063QA
Other languages
English (en)
Inventor
Nikolai Kley
Jan Tavernier
Lenart Zabeau
Erik Depla
Original Assignee
Orionis Biosciences Inc
Orionis Biosciences Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orionis Biosciences Inc, Orionis Biosciences Nv filed Critical Orionis Biosciences Inc
Publication of SG11202001063QA publication Critical patent/SG11202001063QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
SG11202001063QA 2017-08-09 2018-08-08 Clec9a binding agents and use thereof SG11202001063QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762542944P 2017-08-09 2017-08-09
PCT/US2018/045742 WO2019032662A1 (en) 2017-08-09 2018-08-08 CLEC9A BINDING AGENTS AND USES THEREOF

Publications (1)

Publication Number Publication Date
SG11202001063QA true SG11202001063QA (en) 2020-03-30

Family

ID=65272496

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202001063QA SG11202001063QA (en) 2017-08-09 2018-08-08 Clec9a binding agents and use thereof

Country Status (12)

Country Link
US (1) US20210024637A1 (es)
EP (1) EP3665303A4 (es)
JP (2) JP7327885B2 (es)
KR (2) KR102659140B1 (es)
CN (2) CN117924493A (es)
AU (1) AU2018313810A1 (es)
BR (1) BR112020002706A2 (es)
CA (1) CA3069992A1 (es)
IL (1) IL272524A (es)
MX (1) MX2020001513A (es)
SG (1) SG11202001063QA (es)
WO (1) WO2019032662A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017194782A2 (en) * 2016-05-13 2017-11-16 Orionis Biosciences Nv Therapeutic targeting of non-cellular structures
CA3056630A1 (en) 2017-03-15 2018-09-20 Pandion Therapeutics, Inc. Targeted immunotolerance
CA3064435A1 (en) 2017-05-24 2018-11-29 Pandion Therapeutics, Inc. Targeted immunotolerance
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US11896643B2 (en) 2018-02-05 2024-02-13 Orionis Biosciences, Inc. Fibroblast binding agents and use thereof
PL3849614T3 (pl) * 2018-09-11 2024-04-22 Ambrx, Inc. Koniugaty polipeptydu interleukiny-2 i ich zastosowania
CA3133643A1 (en) 2019-03-28 2020-10-01 Orionis Biosciences, Inc. Therapeutic interferon alpha 1 proteins
BR112021023345A2 (pt) 2019-05-20 2022-02-01 Pandion Operations Inc Imunotolerância com alvo em madcam
US20230181758A1 (en) 2019-07-03 2023-06-15 Codiak Biosciences, Inc. Extracellular vesicles targeting dendritic cells and uses thereof
EP4034146A4 (en) * 2019-09-26 2024-03-06 Orionis Biosciences Inc CONJUGATED CHIMERIC PROTEINS
KR20210129489A (ko) 2020-04-20 2021-10-28 에스케이이노베이션 주식회사 배터리 모듈
AU2021341508A1 (en) 2020-09-10 2023-05-25 Precirix N.V. Antibody fragment against fap
WO2022077006A1 (en) * 2020-10-07 2022-04-14 Dren Bio, Inc. Anti-dectin-1 antibodies and methods of use thereof
IL286430A (en) 2021-09-14 2023-04-01 Yeda Res & Dev Multispecific antibodies for use in the treatment of diseases
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
CN114702588B (zh) * 2022-04-27 2022-11-22 博际生物医药科技(杭州)有限公司 抗Nectin-4抗体和双特异性抗体
WO2023213801A1 (en) 2022-05-02 2023-11-09 Precirix N.V. Pre-targeting

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0805159D0 (en) 2008-03-19 2008-04-23 Sancho Madrid David Immune modulation via C-type lectin
EP2424560A4 (en) * 2009-03-23 2013-11-27 Inst Medical W & E Hall Compounds and methods modulating an immune response
US20150132302A1 (en) 2012-05-01 2015-05-14 The University Of Sydney Vaccine and uses thereof
PT2992100T (pt) * 2013-04-29 2019-12-16 Agrosavfe Nv Composições agroquímicas compreendendo anticorpos que se ligam a esfingolípidos
ITTO20130563A1 (it) * 2013-07-05 2015-01-06 Savio Spa Dispositivo per l'apertura e la chiusura di un'anta oscillante apribile verso l'esterno
EP3298131B1 (en) * 2015-05-20 2023-04-26 The Regents of The University of California Method for generating human dendritic cells for immunotherapy
EP3998281A1 (en) * 2016-02-05 2022-05-18 Orionis Biosciences BV Cd8 binding agents
ES2917000T3 (es) * 2016-10-24 2022-07-06 Orionis Biosciences BV Interferón-gamma mutante diana y usos del mismo
US10906985B2 (en) * 2017-02-06 2021-02-02 Orionis Biosciences, Inc. Targeted engineered interferon and uses thereof

Also Published As

Publication number Publication date
AU2018313810A1 (en) 2020-02-27
KR20240055153A (ko) 2024-04-26
JP7327885B2 (ja) 2023-08-16
CN111511764B (zh) 2024-02-06
JP2023060153A (ja) 2023-04-27
US20210024637A1 (en) 2021-01-28
WO2019032662A1 (en) 2019-02-14
CA3069992A1 (en) 2019-02-14
CN117924493A (zh) 2024-04-26
IL272524A (en) 2020-03-31
EP3665303A1 (en) 2020-06-17
CN111511764A (zh) 2020-08-07
MX2020001513A (es) 2020-08-20
JP2020530302A (ja) 2020-10-22
WO2019032662A8 (en) 2020-03-05
KR102659140B1 (ko) 2024-04-19
EP3665303A4 (en) 2021-04-28
KR20200047564A (ko) 2020-05-07
BR112020002706A2 (pt) 2020-08-25

Similar Documents

Publication Publication Date Title
IL272524A (en) CLEC9A binding factors and their use
IL272643A (en) Binders
IL278888A (en) PSMA binding agents and their uses
IL268206A (en) Antibodies directed against bcma and their use
IL264813B (en) 2-oxo-imidazopyridines and their use
IL287291A (en) A protein that binds to rgma and its use
LT3621694T (lt) Lrrc33 inhibitoriai ir jų panaudojimas
IL268288A (en) Binders
SG11202003585VA (en) Anti-vista antibody and use thereof
ZA201906248B (en) Anti-ceacam1 antibody and use thereof
IL265531A (en) N 3 -cyclically substituted thienouraciles and use thereof
PT3544637T (pt) Conjugados omv-antigénio nativos e sua utilização
IL269836B (en) Converted N-arylethyl-2-aminoquinoline-4-carboxamides and their use
HK1231519A1 (zh) 試劑盒及其用途
IL280369A (en) New myokines and uses thereof
IL269843B (en) Converted N-arylethyl-2-arylquinoline-4-carboxamides and their use
GB2562083B (en) Fungicidal composition and use thereof
IL278919A (en) Combinations comprising tropifexor and cenicriviroc
IL284285A (en) Domperidone combinations against neurodegeneration and use
GB201815215D0 (en) Composition and use
GB201713296D0 (en) Binding agents
GB201713298D0 (en) Binding agents
GB201712101D0 (en) nOMV-ANTIGEN CONJUGATES AND USE THEREOF
GB201721668D0 (en) Extract and use thereof
IL252660A0 (en) Compounds characterized by an inverse freezing property and their uses